Get the Stockscreener App
5.61
0.18%
-0.010
After Hours:
5.55
-0.06
-1.07%
Absci Corp stock is traded at $5.61, with a volume of 5.69M.
It is down -0.18% in the last 24 hours and up +83.33% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
See More
Previous Close:
$5.62
Open:
$5.625
24h Volume:
5.69M
Relative Volume:
1.42
Market Cap:
$872.06M
Revenue:
$2.80M
Net Income/Loss:
$-115.18M
P/E Ratio:
-6.621
EPS:
-0.8473
Net Cash Flow:
$-94.03M
1W Performance:
+15.43%
1M Performance:
+83.33%
6M Performance:
+47.24%
1Y Performance:
+95.47%
1-Day Range:
$5.32
$5.75
1-Week Range:
$4.66
$5.75
52-Week Range:
$2.24
$5.75
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
5.61 | 873.61M | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
New Absci hire gets option to buy 276,200 shares at $4.92 - Stock Titan
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Absci (NASDAQ:ABSI) Hits New 1-Year HighStill a Buy? - MarketBeat
Earnings Preview: Absci Corp to Report Financial Results Post-market on May 07 - 富途牛牛
Here is Why Absci Corp. (ABSI) is One of the Best Biotech Penny Stocks to Buy in 2026 - Yahoo Finance
5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
Absci, DigitalOcean and other big stocks moving lower in Wednesday's pre-market session - MSN
Absci (ABSI) Expected to Announce Earnings on Thursday - MarketBeat
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
H.C. Wainwright reiterates Absci stock rating on hair loss data By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Absci stock rating on hair loss data - Investing.com
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates - MSN
Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates - MSN
Absci (NASDAQ:ABSI) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Absci stock surges 22% on hair-loss drug market optimism By Investing.com - Investing.com India
Absci stock surges 22% on hair-loss drug market optimism - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Absci files $400M mixed securities shelf - MSN
Absci climbs on clinical trial acceleration - MSN
Absci Corp Establishes Advisory Board to Advance Endometriosis Drug - HarianBasis.co
Absci Corp. (ABSI) Offering Impressive Upside to Potential Investors - Insider Monkey
Absci announces proposed public offering of common stock - MSN
10 Most Shorted Penny Stocks to Buy - Insider Monkey
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Absci (NASDAQ:ABSI) Shares Up 7.7%Should You Buy? - MarketBeat
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026 - The Manila Times
Absci sets May 7 webcast for Q1 results and business update - Stock Titan
Absci (NASDAQ: ABSI) sets 2026 virtual vote, highlights ABS-201 and Origin-1 AI - Stock Titan
ABSI Stock Climbs As AI Drug Program Gains Traction - StocksToTrade
We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully - 富途牛牛
Absci (NASDAQ:ABSI) Stock Price Up 11%Still a Buy? - MarketBeat
Massachusetts Financial Services Co. MA Cuts Position in Absci Corporation $ABSI - MarketBeat
Absci Highlights AI Antibody Platform, Teases ABS-201 Hair-Loss Data and 2026 Milestones at Needham Conference - MarketBeat
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Redmile funds cut Absci (ABSI) holdings below 5% after share sale - Stock Titan
Absci Corp | SCHEDULE 13D/A: Others - Moomoo
JP Morgan Initiates Overweight Rating on Absci (ABSI) | ABSI Sto - GuruFocus
Portland InnoAbsci's move into generative AI | Why former Hydro Flask CEO joined Puffin - The Business Journals
Absci Corporation (NASDAQ:ABSI) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Absci Stock (ABSI) Opinions on Q4 Earnings and ABS-201 Trial Progress - Quiver Quantitative
ABSI Forecast, Price Target & Analyst Ratings | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):